Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-κB signaling in human arterial smooth muscle cells

Li,Hongli; Xu,Hao; Sun,Baogui

doi:10.3892/mmr.2012.1010

Lipopolysaccharide regulates MMP-9 expression through TLR4/NF-κB signaling in human arterial smooth muscle cells

Authors:
- Hongli Li
- Hao Xu
- Baogui Sun
View Affiliations

Affiliations: Department of Cardiology, Shanghai First People's Hospital, College of Medicine, Shanghai Jiaotong University, Shanghai 200080, P.R. China
Published online on: July 27, 2012 https://doi.org/10.3892/mmr.2012.1010
Pages: 774-778

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Matrix metalloproteinases (MMPs) are critical to vascular smooth muscle cell migration in vivo. The dysregulation of MMPs is involved in the pathogenesis of abnormal arterial remodeling, aneurysm formation and atherosclerotic plaque instability. It has been confirmed that lipopolysaccharides (LPS) constitute a strong risk factor for the development of atherosclerosis. In this study, we aimed to determine a potential mechanism of LPS on MMP-9 expression in human arterial smooth muscle cells (HASMCs). RT-PCR analysis was used to detect MMP-9 mRNA expression and western blot analysis was performed to examine MMP-9 protein expression. An electrophoretic mobility shift assay was also employed to determine NF-κB binding activity. Results showed that LPS induced MMP-9 mRNA and protein expression in HASMCs in a TLR4-dependent manner. Notably, upon blocking the NF-κB binding with pyrrolidine dithiocarbamate, it was demonstrated that the expression of MMP-9 by LPS occurs through TLR4/NF-κB pathways. It was concluded that LPS induced MMP-9 expression through the TLR4/NF-κB pathway. Thus, the TLR4/NF-κB pathway may be involved in the pathogenesis of atherosclerosis.

View Figures

View References

1	Nagase H: Activation mechanisms of matrix metalloproteinases. Biol Chem. 378:151–160. 1997.PubMed/NCBI
2	Creemers EE, Cleutjens JP, Smits JF and Daemen MJ: Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure? Circ Res. 89:201–210. 2001. View Article : Google Scholar : PubMed/NCBI
3	Lancelot E, Amirbekian V, Brigger I, Raynaud JS, Ballet S, David C, Rousseaux O, Le Greneur S, Port M, Lijnen HR, Bruneval P, Michel JB, Ouimet T, Roques B, Amirbekian S, Hyafil F, Vucic E, Aguinaldo JG, Corot C and Fayad ZA: Evaluation of matrix metalloproteinases in atherosclerosis using a novel noninvasive imaging approach. Arterioscler Thromb Vasc Biol. 28:425–432. 2008. View Article : Google Scholar : PubMed/NCBI
4	Furman C, Luo Z, Walsh K, Duverger N, Copin C, Fruchart JC and Rouis M: Systemic tissue inhibitor of metalloproteinase-1 gene delivery reduces neointimal hyperplasia in balloon-injured rat carotid artery. FEBS Lett. 531:122–126. 2002. View Article : Google Scholar : PubMed/NCBI
5	Fedak PW, Moravec CS, McCarthy PM, Altamentova SM, Wong AP, Skrtic M, Verma S, Weisel RD and Li RK: Altered expression of disintegrin metalloproteinases and their inhibitor in human dilated cardiomyopathy. Circulation. 113:238–245. 2006. View Article : Google Scholar : PubMed/NCBI
6	Tziakas DN, Chalikias GK, Papaioakeim M, Hatzinikolaou EI, Stakos DA, Tentes IK, Papanas N, Kortsaris A, Maltezos E and Hatseras DI: Comparison of levels of matrix metalloproteinase-2 and -3 in patients with ischemic cardiomyopathy versus nonischemic cardiomyopathy. Am J Cardiol. 96:1449–1451. 2005. View Article : Google Scholar : PubMed/NCBI
7	Sun Y, Zhang JQ, Zhang J and Lamparter S: Cardiac remodeling by fibrous tissue after infarction in rats. J Lab Clin Med. 135:316–323. 2000. View Article : Google Scholar : PubMed/NCBI
8	Ogawa M, Suzuki J, Hishikari K, Takayama K, Tanaka H and Isobe M: Clarithromycin attenuates acute and chronic rejection via matrix metalloproteinase suppression in murine cardiac transplantation. J Am Coll Cardiol. 51:1977–1985. 2008. View Article : Google Scholar
9	Lee SO, Chang YC, Whang K, Kim CH and Lee IS: Role of NAD(P)H:quinone oxidoreductase 1 on tumor necrosis factor-alpha-induced migration of human vascular smooth muscle cells. Cardiovasc Res. 76:331–339. 2007. View Article : Google Scholar : PubMed/NCBI
10	Otero-Viñas M, Llorente-Cortés V, Peña E, Padró T and Badimon L: Aggregated low density lipoproteins decrease metalloproteinase-9 expression and activity in human coronary smooth muscle cells. Atherosclerosis. 194:326–333. 2007.PubMed/NCBI
11	Cho A and Reidy MA: Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res. 91:845–851. 2002. View Article : Google Scholar : PubMed/NCBI
12	Abe K, Ikeda T, Wake K, Sato T, Sato T and Inoue H: Glycyrrhizin prevents lipopolysaccharide/D-galactosamine-induced liver injury through down-regulation of matrix metalloproteinase-9 in mice. J Pharm Pharmacol. 60:91–97. 2008. View Article : Google Scholar : PubMed/NCBI
13	Pagenstecher A, Stalder AK and Kincaid CL: Regulation of matrix metalloproteinases and their inhibitor genes in lipopolysaccharide-induced endotoxemia in mice. Am J Pathol. 157:197–210. 2000. View Article : Google Scholar : PubMed/NCBI
14	Lin SJ, Lee IT, Chen YH, Lin FY, Sheu LM, Ku HH, Shiao MS, Chen JW and Chen YL: Salvianolic acid B attenuates MMP-2 and MMP-9 expression in vivo in apolipoprotein-E-deficient mouse aorta and in vitro in LPS-treated human aortic smooth muscle cells. J Cell Biochem. 100:372–384. 2007. View Article : Google Scholar : PubMed/NCBI
15	Beswick RA, Zhang H, Marable D, Catravas JD, Hill WD and Webb RC: Long-term antioxidant administration attenuates mineralocorticoid hypertension and renal inflammatory response. Hypertension. 37:781–786. 2001. View Article : Google Scholar
16	Li Hongli and Sun Baogui: Toll-like receptor 4 in atherosclerosis. J Cell Mol Med. 11:88–95. 2007. View Article : Google Scholar : PubMed/NCBI
17	Watari M, Watari H, Nachamkin I and Strauss JF: Lipopolysaccharide induces expression of genes encoding pro-inflammatory cytokines and the elastin-degrading enzyme, cathepsin S, in human cervical smooth-muscle cells. J Soc Gynecol Invest. 7:190–198. 2000. View Article : Google Scholar
18	Fiotti N, Altamura N, Fisicaro M, Carraro N, Adovasio R, Sarra VM, Uxa L, Guarnieri G, Baxter BT and Giansante C: MMP-9 microsatellite polymorphism: association with the progression of intima-media thickening and constrictive remodeling of carotid atherosclerotic plaques. Atherosclerosis. 182:287–292. 2005. View Article : Google Scholar
19	Tsai CS, Lin FY, Chen YH, Yang TL, Wang HJ, Huang GS, Lin CY, Tsai YT, Lin SJ and Li CY: Cilostazol attenuates MCP-1 and MMP-9 expression in vivo in LPS-administrated balloon-injured rabbit aorta and in vitro in LPS-treated monocytic THP-1 cells. J Cell Biochem. 103:54–66. 2008. View Article : Google Scholar : PubMed/NCBI
20	Bea F, Kreuzer J, Preusch M, Schaab S, Isermann B, Rosenfeld ME, Katus H and Blessing E: Melagatran reduces advanced atherosclerotic lesion size and may promote plaque stability in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol. 26:2787–2792. 2006. View Article : Google Scholar : PubMed/NCBI
21	Lee SY, Kim HJ, Lee WJ, Joo SH, Jeon SJ, Kim JW, Kim HS, Han SH, Lee J, Park SH, Cheong JH, Kim WK, Ko KH and Shin CY: Differential regulation of matrix metalloproteinase-9 and tissue plasminogen activator activity by the cyclic-AMP system in lipopolysaccharide-stimulated rat primary astrocytes. Neurochem Res. 33:2324–2334. 2008. View Article : Google Scholar
22	Marcet-Palacios M, Ulanova M, Duta F, Puttagunta L, Munoz S, Gibbings D, Radomski M, Cameron L, Mayers I and Befus AD: The transcription factor Wilms tumor 1 regulates matrix metalloproteinase-9 through a nitric oxide-mediated pathway. J Immunol. 179:256–265. 2007. View Article : Google Scholar : PubMed/NCBI